Fertility and Pregnancy in Patients With Classic Congenital Adrenal Hyperplasia
NCT06153043 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56
Last updated 2024-02-28
Summary
Classic congenital adrenal hyperplasia (CAH) is a rare genetic endocrine disorder. Its prevalence is around 1/15.000. It results from a deficiency in 21-hydroxylase, an adrenal steroidogenic enzyme involved in the biosynthesis of cortisol and aldosterone. Enzyme deficiency in the steroideogenesis pathway leads to cortisol and aldosterone deficiency of varying severity, and to the accumulation of precursors (17OHP and Progesterone), which are diverted to the production of androgens (Testosterone and D4AD).
There are two clinical forms of classical CAH : the salt wasting form and the simple virilizing form, depending on the degree of aldosterone deficiency.
The clinical signs are adrenal insufficiency and hyperandrogenism. Hyperandrogenism manifests itself during foetal life, and may be responsible for virilization of the external genitalia of a female foetus, of varying severity.
The challenge in managing this condition is to find the right therapeutic balance. Hydrocortisone and fludrocortisone supplementation must be adapted to control adrenal insufficiency, and limit hyperandrogenism. It must be sufficient to avoid episodes of acute adrenal insufficiency, but not excessive to avoid complications secondary to hypercorticism.
During childhood, this balance is necessary for growth and pubertal development. However, this balance is difficult to achieve and maintain over time.
In adulthood, the fertility of patients is an important issue. This one remains poorly understood.
It was only after the introduction of cortisol supplementation in the treatment of CAH in the 1950s that the first pregnancies were described. Since when, due to the rarity of the pathology, the number of pregnancies studied has remained low, and the literature has little hindsight on the subject.
This pathology has long been associated with female infertility, due to many factors : biological, mechanical, psychological and sexual, among others. Biological hyperandrogenism may be responsible for chronic dysovulation, and may render the endometrium unsuitable for embryonic implantation. The virilization of the external genitalia and possible complications of pelvic surgery can be an obstacle to sexuality in these patients. They experience sexual difficulties, particularly during penetrative intercourse. The literature also shows that the majority of these patients are single and that their sexual orientation is more likely to be homosexual. Finally, the desire to have children is less prevalent in these patients than in the general population.
The first published studies on the fertility of CAH patients showed a lower pregnancy rate than the general population, but did not take into account the patient' desire to become pregnant.
In 2009, Casteras et al demonstrated for the first time in a cohort of CAH patients that fecundity is preserved in patients with a desire to become pregnant.
It should be noted that the fertility of patients with CAH may evolve in the coming years in France thanks to the new bioethics law voted in 2021, which now allows unmarried patients and patients in homosexual couples to have access to male gamete donation.
In addition, very little is known about the course of pregnancies in patients with CAH. Few pregnancies have been studied to date.
Hormonal balance during pregnancy if difficult to monitor, given the absence of reliable biological makers during this period. In this context, it is complicated to know the impact of the pathology and its balance on the course of the pregnancy.
The latest articles published on the subject of pregnancy complications are contradictory. Some find an increased risk of gestational diabetes. Others find a higher risk of maternal-fetal infection, low weight for gestational age, or congenital malformations than in general population. The increased risk of miscarriage is debated.
On the other hand, articles are unanimous on the most frequent mode of delivery in this population : in the vast majority of cases, patients give birth by ceasarian section, due to their history of pelvic surgery.
It is in context that we wish through this study to make a point of fertility and pregnancy in patients with classical CAH.
Conditions
- Classic Congenital Adrenal Hyperplasia
Interventions
- OTHER
-
Women patients with classical congenital adrenal hyperplasia
The Easily and Médifirst medical files of these patients will be studied in order to collect the desired variables. If the files are incomplete, and if data concerning fertility, pregnancy, and the characteristics of the newborn are missing, patients will be contacted to ask them to answer the questionnaire to obtain this information.
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-01-16
- Primary Completion
- 2024-02-16
- Completion
- 2024-02-16
Countries
- France
Study Locations
More Related Trials
-
Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency.
NCT01862380 ·Status: UNKNOWN ·Phase: NA
-
Gonadal Changes In Congenital Adrenal Hyperplasia Patients
NCT04903587 ·Status: UNKNOWN
-
Fertility And Sexual Function In CAH: CALLIOPE
NCT07099456 ·Status: RECRUITING
-
Final Height in Patients With CAH
NCT04293133 ·Status: UNKNOWN
-
Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia
NCT01771328 ·Status: UNKNOWN ·Phase: PHASE2
-
Growth Hormone Treatment of Young Growth Hormone-Deficient Adults
NCT00187993 ·Status: UNKNOWN
-
Questionnaire Study to Assess the Outcomes of the Management of Congenital Adrenal Hyperplasia Individuals
NCT05228652 ·Status: UNKNOWN
-
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment
NCT03760835 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia
NCT05663320 ·Status: WITHDRAWN ·Phase: NA
-
Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
NCT01859312 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia
NCT02349503 ·Status: WITHDRAWN ·Phase: PHASE1
-
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
NCT04806451 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Natural History Study of Patients With Excess Androgen
NCT00250159 ·Status: RECRUITING
-
Effects and Importance of Epinephrine/Adrenalin Deficiency in CAH
NCT05162950 ·Status: UNKNOWN
-
Effects of Pioglitazone in Congenital Adrenal Hyperplasia
NCT00151710 ·Status: COMPLETED ·Phase: NA
-
Long-term Outcome of GnRH Analogues Treatment of Children With Idiopathic Central Precocious Puberty
NCT02790112 ·Status: UNKNOWN ·Phase: NA
-
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
NCT05669950 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency
NCT04536662 ·Status: UNKNOWN ·Phase: PHASE4
-
Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders
NCT01165619 ·Status: TERMINATED
-
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
NCT04490915 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
NCT00921609 ·Status: COMPLETED
-
Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH
NCT06449456 ·Status: COMPLETED
-
Biological Age in Children With GH Deficiency Undergoing Hormone Replacement Therapy
NCT06294860 ·Status: COMPLETED
-
Androgen Reduction in Congenital Adrenal Hyperplasia
NCT03548246 ·Status: WITHDRAWN ·Phase: PHASE2
-
X-linked Hypophosphatemia and FGF21
NCT03596554 ·Status: COMPLETED